HKSH Cancer Centre’s Precision Targeting Technologies Leading the Evolution of “Hypofractionation”

2026-03-20 – Press Releases – www.prnewswire.com

Asia’s First Study: 5 Sessions of Proton Therapy to Control Early-Stage Prostate Cancer HONG KONG, March 20, 2026 /PRNewswire/ — HKSH Medical Group (HKSH) today announced the results of Asia’s first clinical study on early-stage prostate cancer patients receiving five-session of proton…

Read the full article here.